摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-cyclohexyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine-2-amine | 342651-31-4

中文名称
——
中文别名
——
英文名称
N-cyclohexyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine-2-amine
英文别名
N-cyclohexyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine;N-cyclohexyl-4-(4-(methylsulfonyl)phenyl)-6-(trifluoromethyl)pyrimidin-2-amine;N-cyclohexyl-4-(4-methylsulfonylphenyl)-6-(trifluoromethyl)pyrimidin-2-amine
N-cyclohexyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine-2-amine化学式
CAS
342651-31-4
化学式
C18H20F3N3O2S
mdl
——
分子量
399.437
InChiKey
SFTDLGJIDMULGE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    80.3
  • 氢给体数:
    1
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-(methylsulfonyl)-4-(4-(methylsulfonyl)phenyl)-6-(trifluoromethyl)pyrimidine环己胺乙腈 为溶剂, 反应 26.0h, 以52%的产率得到N-cyclohexyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine-2-amine
    参考文献:
    名称:
    Pyrimidine derivatives
    摘要:
    该发明提供了式(I)的化合物及其药学上可接受的衍生物,其中:R1和R2分别选自H、C1-6烷基、C2-6烯基、C3-6炔基、C3-10环烷基C0-6烷基或C4-12桥环烷烃;R3为C1-6烷基或NH2。式(I)的化合物是COX-2的有效选择性抑制剂,并可用于治疗疼痛、发热、炎症和各种疾病和病症。
    公开号:
    US06780869B1
点击查看最新优质反应信息

文献信息

  • Pyrimidine derivatives
    申请人:SmithKline Beecham Corporation
    公开号:US06780869B1
    公开(公告)日:2004-08-24
    The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof, in which: R1 and R2 are independently selected from H, C1-6 alkyl, C2-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl or C4-12bridged cycloalkane; and R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of pain, fever, inflammation and a variety of conditions and diseases.
    该发明提供了式(I)的化合物及其药学上可接受的衍生物,其中:R1和R2分别选自H、C1-6烷基、C2-6烯基、C3-6炔基、C3-10环烷基C0-6烷基或C4-12桥环烷烃;R3为C1-6烷基或NH2。式(I)的化合物是COX-2的有效选择性抑制剂,并可用于治疗疼痛、发热、炎症和各种疾病和病症。
  • PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2
    申请人:GLAXO GROUP LIMITED
    公开号:EP1235812A2
    公开(公告)日:2002-09-04
  • US6780869B1
    申请人:——
    公开号:US6780869B1
    公开(公告)日:2004-08-24
  • [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
    申请人:GLAXO GROUP LTD
    公开号:WO2001038311A2
    公开(公告)日:2001-05-31
    The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof, in which: R?1 and R2¿ are independently selected from H, C¿1-6?alkyl, C2-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl or C4-12bridged cycloalkane; and R?3¿ is C¿1-6?alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.
  • Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors
    作者:Martin E. Swarbrick、Paul J. Beswick、Robert J. Gleave、Richard H. Green、Sharon Bingham、Chas Bountra、Malcolm C. Carter、Laura J. Chambers、Iain P. Chessell、Nick M. Clayton、Sue D. Collins、John A. Corfield、C. David Hartley、Savvas Kleanthous、Paul F. Lambeth、Fiona S. Lucas、Neil Mathews、Alan Naylor、Lee W. Page、Jeremy J. Payne、Neil A. Pegg、Helen S. Price、John Skidmore、Alexander J. Stevens、Richard Stocker、Sharon C. Stratton、Alastair J. Stuart、Joanne O. Wiseman
    DOI:10.1016/j.bmcl.2009.02.085
    日期:2009.8
    A novel series of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidine-based cyclooxygenase-2 (COX-2) inhibitors, which have a different arrangement of substituents compared to the more common 1,2-diarylheterocycle based molecules, have been discovered. For example, 2-(butyloxy)-4-[4(methylsulfonyl) phenyl]-6-(trifluoromethyl) pyrimidine (47), a member of the 2- pyrimidinyl ether series, has been shown to be a potent and selective inhibitor with a favourable pharmacokinetic pro. le, high brain penetration and good efficacy in rat models of hypersensitivity. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多